AEBSF

Description

AEBSF, CAS 30827-99-7, is a specific irreversible inhibitor of chymotrypsin, kallikrein, plasmin, thrombin, trypsin, and related thrombolytic enzymes. A nontoxic alternative to PMSF and DFP.

Specific irreversible inhibitor of serine proteases. Reacts covalently with a serine at the active site. Inhibits chymotrypsin, kallikrein, plasmin, thrombin, trypsin, and related thrombolytic enzymes. Stable, nontoxic alternative to PMSF . Used at the same molar concentration (0.1-1.0 mM) as PMSF for most applications. Exhibits low inhibitory activity towards proteinase K.

Specific, irreversible inhibitor of serine proteases. Inhibits chymotrypsin, kallikrein, plasmin, thrombin, trypsin, and related thrombolytic enzymes. Stable, nontoxic alternative to PMSF. A β-secretase inhibitor that inhibits β-amyloid peptide (Aβ) production and enhances amyloid precursor protein (sAPPUα) secretion in several cell lines at millimolar concentrations. Use at the same molar concentrations (0.1-1.0 mM) as PMSF for most applications. Also available as a 50 mM solution in H2O.

Biochem/physiol Actions

Primary Target
chymotrypsin
Product does not compete with ATP.

Warning

Packaged under inert gas

Reconstitution

Following reconstitution, store in the refrigerator (4°C). Aqueous stock solutions are stable for up to 2 months at 4°C. Slight hydrolysis occurs at alkaline pH (8-9).

References

Citron, M., et al. 1996. Neuron 17, 171.
Ohkubo, I., et al. 1994. J. Biochem. 116, 1182.
Mintz, G.R. 1993. BioPharm. 6, 34.
Lawson, W.B., et al. 1982. Folia Haematol.109, 52.
Markwardt, F., et al. 1974. Biochem. Pharmacol.23, 2247.
Markwardt, F., et al. 1973. Thromb. Res.2, 343.
Baker, B.R., and Cory, M. 1971. J. Med. Chem.14, 119.

Documents

INFO

COA

SDS 

Disclaimer: For laboratory research use only.